Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients and Sample Collection
2.2. Clinical Features
2.3. Serological Testing for Anti-CN1A Antibodies
2.4. Statistical Analysis
3. Results
4. Discussion
Study Limits
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Griggs, R.C.; Askanas, V.; DiMauro, S.; Engel, A.; Karpati, G.; Mendell, J.R.; Rowland, L.P. Inclusion body myositis and myopathies. Ann. Neurol. 1995, 38, 705–713. [Google Scholar] [CrossRef]
- Askanas, V.; Alvarez, R.B.; Mirabella, M.; Engel, W.K. Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann. Neurol. 1996, 39, 389–391. [Google Scholar] [CrossRef]
- Needham, M.; Corbett, A.; Day, T.; Christiansen, F.; Fabian, V.; Mastaglia, F.L. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J. Clin. Neurosci. 2008, 15, 1350–1353. [Google Scholar] [CrossRef] [PubMed]
- Rose, M. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 2013, 23, 1044–1055. [Google Scholar] [CrossRef]
- Tasca, G.; Monforte, M.; De Fino, C.; Kley, R.A.; Ricci, E.; Mirabella, M. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 2015, 52, 956–962. [Google Scholar] [CrossRef] [PubMed]
- Salajegheh, M.; Lam, T.; Greenberg, S.A. Autoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis. PLoS ONE 2011, 6, e20266. [Google Scholar] [CrossRef] [PubMed]
- Pluk, H.; Van Hoeve, B.J.A.; Van Dooren, S.H.J.; Stammen-Vogelzangs, J.; Van Der Heijden, A.; Schelhaas, H.J.; Verbeek, M.M.; Badrising, U.A.; Arnardottir, S.; Gheorghe, K.; et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann. Neurol. 2012, 73, 397–407. [Google Scholar] [CrossRef]
- Larman, H.B.; Salajegheh, M.; Nazareno, R.; Lam, T.; Sauld, J.; Steen, H.; Kong, S.W.; Pinkus, J.L.; Amato, A.A.; Elledge, S.J.; et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann. Neurol. 2013, 73, 408–418. [Google Scholar] [CrossRef]
- Greenberg, S.A. Cytoplasmic 5′-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve 2014, 50, 488–492. [Google Scholar] [CrossRef]
- Limaye, V.S.; Lester, S.; Blumbergs, P.; Greenberg, S.A. Anti- C N1A antibodies in South Australian patients with inclusion body myositis. Muscle Nerve 2016, 53, 654–655. [Google Scholar] [CrossRef] [PubMed]
- Goyal, N.A.; Cash, T.M.; Alam, U.; Enam, S.; Tierney, P.; Araujo, N.; Mozaffar, F.H.; Pestronk, A.; Mozaffar, T. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J. Neurol. Neurosurg. Psychiatry 2016, 87, 373–378. [Google Scholar] [CrossRef] [PubMed]
- Herbert, M.K.; Stammen-Vogelzangs, J.; Verbeek, M.M.; Rietveld, A.; Lundberg, I.E.; Chinoy, H.; Lamb, J.A.; Cooper, R.G.; Roberts, M.; Badrising, U.A.; et al. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann. Rheum. Dis. 2016, 75, 696–701. [Google Scholar] [CrossRef] [PubMed]
- Tawara, N.; Yamashita, S.; Zhang, X.; Korogi, M.; Zhang, Z.; Doki, T.; Matsuo, Y.; Nakane, S.; Maeda, Y.; Sugie, K.; et al. Pathomechanisms of anti-cytosolic 5′-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann. Neurol. 2017, 81, 512–525. [Google Scholar] [CrossRef]
- Lilleker, J.B.; Rietveld, A.; Pye, S.R.; Mariampillai, K.; Benveniste, O.; Peeters, M.T.J.; Miller, J.A.L.; Hanna, M.G.; Machado, P.M.; Parton, M.J.; et al. Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann. Rheum. Dis. 2017, 76, 862–868. [Google Scholar] [CrossRef] [PubMed]
- Felice, K.J.; Whitaker, C.H.; Wu, Q.; Larose, D.T.; Shen, G.; Metzger, A.L.; Barton, R.W. Sensitivity and clinical utility of the anti-cytosolic 5′-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center. Neuromuscul. Disord. 2018, 28, 660–664. [Google Scholar] [CrossRef] [PubMed]
- Herbert, M.K.; Pruijn, G.J. Novel serology testing for sporadic inclusion body myositis. Curr. Opin. Rheumatol. 2015, 27, 595–600. [Google Scholar] [CrossRef] [PubMed]
- Amlani, A.; Choi, M.Y.; Tarnopolsky, M.; Brady, L.; Clarke, A.E.; La Torre, I.G.-D.; Mahler, M.; Schmeling, H.; Barber, C.E.; Jung, M.; et al. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. Front. Immunol. 2019, 10, 745. [Google Scholar] [CrossRef]
- Lloyd, T.E.; Christopher-Stine, L.; Pinal-Fernandez, I.; Tiniakou, E.; Petri, M.; Baer, A.; Danoff, S.K.; Pak, K.; Casciola-Rosen, L.A.; Mammen, A.L. Cytosolic 5′-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Rheum. 2016, 68, 66–71. [Google Scholar] [CrossRef]
- Jackson, C.; Barohn, R.; Gronseth, G.; Pandya, S.; Herbelin, L. The Muscle Study Group (MSG) Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity. Muscle Nerve 2008, 37, 473–476. [Google Scholar] [CrossRef]
- Kramp, S.L.; Karayev, D.; Shen, G.; Metzger, A.L.; Morris, R.I.; Karayev, E.; Lam, Y.; Kazdan, R.M.; Pruijn, G.J.M.; Saschenbrecker, S.; et al. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis. Autoimmun. Highlights 2016, 7, 1–9. [Google Scholar] [CrossRef]
- Paul, P.; Liewluck, T.; Ernste, F.C.; Mandrekar, J.; Milone, M. Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis. Muscle Nerve 2021, 63, 490–496. [Google Scholar] [CrossRef]
- Badrising, U.A.; Maat-Schieman, M.L.; Ferrari, M.D.; Zwinderman, A.H.; Wessels, J.A.; Breedveld, F.C.; Van Doorn, P.A.; Van Engelen, B.G.; Hoogendijk, J.E.; Höweler, C.J.; et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann. Neurol. 2002, 51, 369–372. [Google Scholar] [CrossRef] [PubMed]
- Walter, M.C.; Lochmüller, H.; Toepfer, M.; Schlotter, B.; Reilich, P.; Schröder, M.; Müller-Felber, W.; Pongratz, D. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J. Neurol. 2000, 247, 22–28. [Google Scholar] [CrossRef] [PubMed]
- Dalakas, M.C.; Koffman, B.; Fujii, M.; Spector, S.; Sivakumar, K.; Cupler, E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001, 56, 323–327. [Google Scholar] [CrossRef]
- Molberg, Ø.; Dobloug, C. Epidemiology of sporadic inclusion body myositis. Curr. Opin. Rheumatol. 2016, 28, 657–660. [Google Scholar] [CrossRef]
- Mulcahy, K.P.; Langdon, P.C.; Mastaglia, F. Dysphagia in Inflammatory Myopathy: Self-report, Incidence, and Prevalence. Dysphagia 2011, 27, 64–69. [Google Scholar] [CrossRef]
- Lotz, B.P.; Engel, A.G.; Nishino, H.; Stevens, J.C.; Litchy, W.J. INCLUSION BODY MYOSITIS. Brain 1989, 112, 727–747. [Google Scholar] [CrossRef]
- Cox, F.M.; Verschuuren, J.J.; Verbist, B.M.; Niks, E.H.; Wintzen, A.R.; Badrising, U.A. Detecting dysphagia in inclusion body myositis. J. Neurol. 2009, 256, 2009–2013. [Google Scholar] [CrossRef]
- Shibata, S.; Izumi, R.; Hara, T.; Ohshima, R.; Nakamura, N.; Suzuki, N.; Kato, K.; Katori, Y.; Tateyama, M.; Kuroda, H.; et al. Five-year history of dysphagia as a sole initial symptom in inclusion body myositis. J. Neurol. Sci. 2017, 381, 325–327. [Google Scholar] [CrossRef] [PubMed]
- Langdon, P.C.; Mulcahy, K.; Shepherd, K.L.; Low, V.H.; Mastaglia, F.L. Pharyngeal Dysphagia in Inflammatory Muscle Diseases Resulting from Impaired Suprahyoid Musculature. Dysphagia 2011, 27, 408–417. [Google Scholar] [CrossRef]
- Jones, K.; Pitceathly, R.D.S.; Rose, M.R.; McGowan, S.; Hill, M.; Badrising, U.A.; Hughes, T. Interventions for dysphagia in long-term, progressive muscle disease. Cochrane Database Syst. Rev. 2016, 2, CD004303. [Google Scholar] [CrossRef] [PubMed]
- Mohannak, N.; Pattison, G.; Hird, K.; Needham, M. Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges. Int. J. Gen. Med. 2019, 12, 465–474. [Google Scholar] [CrossRef]
- Price, M.A.; Barghout, V.; Benveniste, O.; Christopher-Stine, L.; Corbett, A.; De Visser, M.; Hilton-Jones, D.; Kissel, J.T.; Lloyd, T.E.; Lundberg, I.E.; et al. Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. J. Neuromuscul. Dis. 2016, 3, 67–75. [Google Scholar] [CrossRef] [PubMed]
- Shelly, S.; Mielke, M.M.; Mandrekar, J.; Milone, M.; Ernste, F.C.; Naddaf, E.; Liewluck, T. Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study. Neurology 2021, 20. [Google Scholar] [CrossRef]
s-IBM n = 62 | |
---|---|
Female sex, n (%) | 23 (37.1) |
Age, years | 67.3 (9.6) |
Disease duration, years | 8.3 (7.5) |
Age at onset, years | 59.0 (10.0) |
Diagnostic delay, years | 5.0 (4.0) |
CK levels (UI/L) | 675.5 (481.0) |
Quadriceps MRC (0–5) | 3.2 (1.3) |
Dysphagia, n (%) | 31 (50.0) |
Ambulant patients, n (%) | 58 (93.6) |
2011 ENMC criteria | |
Clinicopathologically defined IBM | 41 (66.1) |
Clinically defined IBM | 14 (22.6) |
Probable IBM | 7 (11.3) |
Symptoms at onset, n (%) | |
Proximal lower limb weakness | 46 (74.2) |
Distal upper limb weakness | 11 (17.7) |
Dysphagia | 5 (8.1) |
IBMFRS score | 27.4 (7.7) |
IIMs Other than s-IBM n = 62 | |
---|---|
Female sex, n (%) | 38 (61.3) |
Age, years | 63.6 (14.0) |
Inflammatory myopathy classification, n (%) | |
Immune-mediated necrotizing myopathy | 28 (45.2) |
Dermatomyositis | 20 (32.2) |
Polymyositis | 10 (16.1) |
Overlap Myositis | 4 (6.5) |
Anti-cN1A Positive n = 23 | Anti-cN1A Negative n = 39 | p Value | |
---|---|---|---|
Female sex, % | 39.1 | 38.5 | 0.958 |
Age at onset, years | 59.7 (9.8) | 58.6 (10.2) | 0.664 |
Diagnostic delay, years | 5.3 (4.6) | 4.8 (3.7) | 0.640 |
Age, years | 68.9 (8.0) | 66.3 (10.4) | 0.318 |
Disease duration, years | 9.1 (6.4) | 7.8 (5.8) | 0.391 |
CK levels (UI/L) | 782.0 (674.4) | 606.6 (289.4) | 0.185 |
Dysphagia, % | 60.9 | 43.6 | 0.189 |
Ambulant patients, % | 91.3 | 94.9 | 0.581 |
MRC quadriceps (range 0–5) | 2.9 (1.4) | 3.3 (1.2) | 0.196 |
IBMFRS score (range 0–40) | 25.9 (8.4) | 28.4 (7.1) | 0.253 |
IBMFRS item 1 (Dysphagia) | 2.8 (1.1) | 3.3 (0.9) | 0.045 |
IBMFRS item 1 ≤ 2, % (whole cohort) | 52.4 | 9.7 | <0.001 |
IBMFRS item 2–5 (Upper limb) | 11.2 (3.5) | 12.4 (3.5) | 0.199 |
IBMFRS item 8–10 (Lower limb) | 5.9 (2.8) | 6.6 (2.5) | 0.381 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lucchini, M.; Maggi, L.; Pegoraro, E.; Filosto, M.; Rodolico, C.; Antonini, G.; Garibaldi, M.; Valentino, M.L.; Siciliano, G.; Tasca, G.; et al. Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis. Cells 2021, 10, 1146. https://doi.org/10.3390/cells10051146
Lucchini M, Maggi L, Pegoraro E, Filosto M, Rodolico C, Antonini G, Garibaldi M, Valentino ML, Siciliano G, Tasca G, et al. Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis. Cells. 2021; 10(5):1146. https://doi.org/10.3390/cells10051146
Chicago/Turabian StyleLucchini, Matteo, Lorenzo Maggi, Elena Pegoraro, Massimiliano Filosto, Carmelo Rodolico, Giovanni Antonini, Matteo Garibaldi, Maria Lucia Valentino, Gabriele Siciliano, Giorgio Tasca, and et al. 2021. "Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis" Cells 10, no. 5: 1146. https://doi.org/10.3390/cells10051146
APA StyleLucchini, M., Maggi, L., Pegoraro, E., Filosto, M., Rodolico, C., Antonini, G., Garibaldi, M., Valentino, M. L., Siciliano, G., Tasca, G., De Arcangelis, V., De Fino, C., & Mirabella, M. (2021). Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis. Cells, 10(5), 1146. https://doi.org/10.3390/cells10051146